These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26298540)

  • 1. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment.
    van de Bilt MT; Prado CM; Ojopi EP; Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF
    Schizophr Res; 2015 Oct; 168(1-2):587-8. PubMed ID: 26298540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial.
    Jürgens G; Andersen SE; Rasmussen HB; Werge T; Jensen HD; Kaas-Hansen BS; Nordentoft M
    JAMA Netw Open; 2020 Dec; 3(12):e2027909. PubMed ID: 33284338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study.
    Naujokaitis D; Asmoniene V; Kadusevicius E
    Medicine (Baltimore); 2021 Mar; 100(11):e24545. PubMed ID: 33725937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
    Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
    Psychiatr Danub; 2010 Jun; 22(2):335-7. PubMed ID: 20562776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
    Dahl ML
    Clin Pharmacokinet; 2002; 41(7):453-70. PubMed ID: 12083975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?
    Jürgens G; Rasmussen HB; Werge T; Dalhoff K; Nordentoft M; Andersen SE
    J Clin Psychopharmacol; 2012 Feb; 32(1):100-5. PubMed ID: 22198443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.
    Dorado P; Peñas-Lledó EM; Llerena A
    Pharmacogenomics; 2007 Nov; 8(11):1597-608. PubMed ID: 18034624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP 2D6 polymorphism and antipsychotic therapy.
    Plesnicar BK; Dolzan V; Zalar B
    Psychiatr Danub; 2008 Sep; 20(3):369-71. PubMed ID: 18827765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of CYP2D6 and CYP2C19 polymorphisms on suicidal behavior and substance abuse disorder among patients with schizophrenia: a retrospective study.
    Kobylecki CJ; Hansen T; Timm S; Wang A; Jakobsen KD; Sørensen HJ; Rasmussen HB; Werge T
    Ther Drug Monit; 2008 Jun; 30(3):265-70. PubMed ID: 18520596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics.
    Austin-Zimmerman I; Wronska M; Wang B; Irizar H; Thygesen JH; Bhat A; Denaxas S; Fatemifar G; Finan C; Harju-Seppänen J; Giannakopoulou O; Kuchenbaecker K; Zartaloudi E; McQuillin A; Bramon E
    Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?
    Herbild L; Andersen SE; Werge T; Rasmussen HB; Jürgens G
    Basic Clin Pharmacol Toxicol; 2013 Oct; 113(4):266-72. PubMed ID: 23731498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 and CYP2C19 genotyping in psychiatric patients on psychotropic medication in the former Dutch Antilles.
    Koopmans AB; Vinkers DJ; Gelan PJ; Hoek HW; van Harten PN
    Pharmacogenomics; 2017 Jul; 18(10):1003-1012. PubMed ID: 28639468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
    van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
    Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 mutations and therapeutic outcome in schizophrenic patients.
    Hamelin BA; Dorson PG; Pabis D; Still D; Bouchard RH; Pourcher E; Rail J; Turgeon J; Crismon ML
    Pharmacotherapy; 1999 Sep; 19(9):1057-63. PubMed ID: 10610012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry.
    Kropp S; Lichtinghagen R; Winterstein K; Schlimme J; Schneider U
    Clin Lab; 2006; 52(5-6):237-40. PubMed ID: 16812949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.
    Ganoci L; Trkulja V; Živković M; Božina T; Šagud M; Lovrić M; Božina N
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110042. PubMed ID: 32682874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response.
    Yadav SS; Ruwali M; Pant MC; Shukla P; Singh RL; Parmar D
    Mutat Res; 2010 Feb; 684(1-2):49-55. PubMed ID: 19954746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics.
    Kohlrausch FB; Gama CS; Lobato MI; Belmonte-de-Abreu P; Callegari-Jacques SM; Gesteira A; Barros F; Carracedo A; Hutz MH
    Pharmacogenet Genomics; 2008 Jul; 18(7):599-609. PubMed ID: 18551040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.